In the report, when you read "equivalent to non-injured animals" and "also significantly reducedback to non-injured levels", there is a sense of optimism and hope that this could develop into a significant biotech company. Currently well funded and hopefully will attract support in the future, Early days, but exciting future.
Ann: ARG-007 Protects Brain Cells in Moderate TBI Model, page-3
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
68.0¢ |
Change
-0.005(0.73%) |
Mkt cap ! $87.10M | |||
| Open | High | Low | Value | Volume |
| 68.0¢ | 69.0¢ | 66.5¢ | $77.03K | 113.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3112 | 68.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 69.0¢ | 1500 | 1 |
View Market Depth
| Last trade - 15.41pm 02/10/2024 (20 minute delay) ? |
| AGN (ASX) Chart |